Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NKTR-118

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Opioid-induced constipation (OIC) and other gastrointestinal (GI) symptoms of opioid-induced bowel dysfunction (OIBD… Expand
  • figure 1
  • table 1
  • table 3
Is this relevant?
2015
2015
This randomized, double-blind, placebo-controlled, ascending-dose, crossover study evaluated single oral doses of naloxegol (NKTR… Expand
Is this relevant?
2015
2015
Opioid-induced constipation (OIC) is the most common and often a treatment-limiting adverse event (AE) of opioid therapy for… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Naloxegol (previously known as NKTR-118) is a peripherally acting μ-opioid receptor antagonist engineered using polymer conjugate… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2013
2013
The article by Webster et al. focused on the use of naloxegol in opioid-induced constipation (OIC) is important, as both OIC and… Expand
Is this relevant?
Review
2011
Review
2011
There has been an alarming increase in the prescription of opiates and opioids for chronic non-cancer pain in the past 15 years… Expand
  • table 1
  • figure 1
Is this relevant?
2009
2009
NKTR-118, a novel PEGylated naloxol conjugate, is an oral, once daily investigational agent in development for treatment of… Expand
  • figure 1
Is this relevant?
2009
2009
AstraZeneca has signed a licensing deal with Nektar Therapeutics to develop and market the latter’s two drugs, NKTR-118 and NKTR… Expand
Is this relevant?